U.S. markets close in 3 hours 13 minutes
  • S&P 500

    4,151.82
    -33.65 (-0.80%)
     
  • Dow 30

    33,999.50
    -201.17 (-0.59%)
     
  • Nasdaq

    13,844.85
    -207.49 (-1.48%)
     
  • Russell 2000

    2,223.97
    -38.70 (-1.71%)
     
  • Crude Oil

    63.30
    +0.17 (+0.27%)
     
  • Gold

    1,769.60
    -10.60 (-0.60%)
     
  • Silver

    25.74
    -0.37 (-1.42%)
     
  • EUR/USD

    1.2038
    +0.0058 (+0.48%)
     
  • 10-Yr Bond

    1.5890
    +0.0160 (+1.02%)
     
  • GBP/USD

    1.3984
    +0.0144 (+1.04%)
     
  • USD/JPY

    108.0680
    -0.7150 (-0.66%)
     
  • BTC-USD

    54,943.96
    -18.38 (-0.03%)
     
  • CMC Crypto 200

    1,242.68
    -56.27 (-4.33%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Vericel to Participate in the BTIG Virtual MedTech Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vericel Corporation
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18, 2021, at 3:00p.m. Eastern Time.

A live webcast of the event will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

Investor Contacts:
Chad Rubin
Solebury Trout
crubin@troutgroup.com
+1 646-378-2947